These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 32535481)

  • 1. Efficacy and safety of Abelmoschus manihot for IgA nephropathy: A multicenter randomized clinical trial.
    Li P; Lin H; Ni Z; Zhan Y; He Y; Yang H; Fang J; Wang N; Li W; Cai G; Chen Y; Zhang P; Wang X; Chen Q; Li Z; Sun X; Chen X
    Phytomedicine; 2020 May; 76():153231. PubMed ID: 32535481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abelmoschus manihot - a traditional Chinese medicine versus losartan potassium for treating IgA nephropathy: study protocol for a randomized controlled trial.
    Li P; Chen YZ; Lin HL; Ni ZH; Zhan YL; Wang R; Yang HT; Fang JA; Wang NS; Li WG; Sun XF; Chen XM
    Trials; 2017 Apr; 18(1):170. PubMed ID: 28395659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of Abelmoschus manihot for primary glomerular disease: a prospective, multicenter randomized controlled clinical trial.
    Zhang L; Li P; Xing CY; Zhao JY; He YN; Wang JQ; Wu XF; Liu ZS; Zhang AP; Lin HL; Ding XQ; Yin AP; Yuan FH; Fu P; Hao L; Miao LN; Xie RJ; Wang R; Zhou CH; Guan GJ; Hu Z; Lin S; Chang M; Zhang M; He LQ; Mei CL; Wang L; Chen X
    Am J Kidney Dis; 2014 Jul; 64(1):57-65. PubMed ID: 24631042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of Abelmoschus manihot in treating chronic kidney diseases: A multicentre, open-label and single-arm clinical trial.
    Sun X; Li P; Lin H; Ni Z; Zhan Y; Cai G; Liu C; Chen Q; Wang W; Wang X; Zhang P; Li P; Liang M; Zheng H; Wang N; Miao L; Jin R; Guo Z; Wang Y; Chen X
    Phytomedicine; 2022 May; 99():154011. PubMed ID: 35278897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment effects of Chinese medicine (Yi-Qi-Qing-Jie herbal compound) combined with immunosuppression therapies in IgA nephropathy patients with high-risk of end-stage renal disease (TCM-WINE): study protocol for a randomized controlled trial.
    Li S; Li JP
    Trials; 2020 Jan; 21(1):31. PubMed ID: 31907076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of Mycophenolate Mofetil Among Patients With Progressive IgA Nephropathy: A Randomized Clinical Trial.
    Hou FF; Xie D; Wang J; Xu X; Yang X; Ai J; Nie S; Liang M; Wang G; Jia N;
    JAMA Netw Open; 2023 Feb; 6(2):e2254054. PubMed ID: 36745456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Randomized Controlled Trial.
    Liu LJ; Yang YZ; Shi SF; Bao YF; Yang C; Zhu SN; Sui GL; Chen YQ; Lv JC; Zhang H
    Am J Kidney Dis; 2019 Jul; 74(1):15-22. PubMed ID: 30922594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
    Rovin BH; Barratt J; Heerspink HJL; Alpers CE; Bieler S; Chae DW; Diva UA; Floege J; Gesualdo L; Inrig JK; Kohan DE; Komers R; Kooienga LA; Lafayette R; Maes B; Małecki R; Mercer A; Noronha IL; Oh SW; Peh CA; Praga M; Preciado P; Radhakrishnan J; Rheault MN; Rote WE; Tang SCW; Tesar V; Trachtman H; Trimarchi H; Tumlin JA; Wong MG; Perkovic V;
    Lancet; 2023 Dec; 402(10417):2077-2090. PubMed ID: 37931634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy.
    Hogg RJ; Bay RC; Jennette JC; Sibley R; Kumar S; Fervenza FC; Appel G; Cattran D; Fischer D; Hurley RM; Cerda J; Carter B; Jung B; Hernandez G; Gipson D; Wyatt RJ
    Am J Kidney Dis; 2015 Nov; 66(5):783-91. PubMed ID: 26209543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of Shenyankangfu Tablet, a Chinese patent medicine, for primary glomerulonephritis: A multicenter randomized controlled trial.
    Wu J; Duan SW; Yang HT; Deng YY; Li W; He YN; Ni ZH; Zhan YL; Lin S; Guo ZY; Zhu J; Fang JA; Liu XS; Wang LH; Wang R; Wang NS; Cheng XH; He LQ; Luo P; Sun SR; Sun JF; Yin AP; Jiang GR; Chen HY; Liu WH; Lin HL; Liang M; Ma L; Chen M; Song LQ; Chen J; Zhu Q; Xing CY; Li Y; Gao JN; Li RS; Li Y; Zhang H; Lu Y; Zhou QL; Fu JZ; He Q; Cai GY; Chen XM
    J Integr Med; 2021 Mar; 19(2):111-119. PubMed ID: 33589406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.
    Manno C; Torres DD; Rossini M; Pesce F; Schena FP
    Nephrol Dial Transplant; 2009 Dec; 24(12):3694-701. PubMed ID: 19628647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of traditional chinese medicine (Shenqi particle) for patients with idiopathic membranous nephropathy: a multicenter randomized controlled clinical trial.
    Chen Y; Deng Y; Ni Z; Chen N; Chen X; Shi W; Zhan Y; Yuan F; Deng W; Zhong Y
    Am J Kidney Dis; 2013 Dec; 62(6):1068-76. PubMed ID: 23810688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.
    Lv J; Zhang H; Wong MG; Jardine MJ; Hladunewich M; Jha V; Monaghan H; Zhao M; Barbour S; Reich H; Cattran D; Glassock R; Levin A; Wheeler D; Woodward M; Billot L; Chan TM; Liu ZH; Johnson DW; Cass A; Feehally J; Floege J; Remuzzi G; Wu Y; Agarwal R; Wang HY; Perkovic V;
    JAMA; 2017 Aug; 318(5):432-442. PubMed ID: 28763548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.
    Lv J; Wong MG; Hladunewich MA; Jha V; Hooi LS; Monaghan H; Zhao M; Barbour S; Jardine MJ; Reich HN; Cattran D; Glassock R; Levin A; Wheeler DC; Woodward M; Billot L; Stepien S; Rogers K; Chan TM; Liu ZH; Johnson DW; Cass A; Feehally J; Floege J; Remuzzi G; Wu Y; Agarwal R; Zhang H; Perkovic V;
    JAMA; 2022 May; 327(19):1888-1898. PubMed ID: 35579642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Effectiveness and Safety of
    Jia Q; Guo J; Cai Y; Huang W; Zhu Z; Xia C; Guo K; Shang H; Liu Y; Liu W
    Evid Based Complement Alternat Med; 2022; 2022():9730753. PubMed ID: 36248420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial.
    Lafayette R; Kristensen J; Stone A; Floege J; Tesař V; Trimarchi H; Zhang H; Eren N; Paliege A; Reich HN; Rovin BH; Barratt J;
    Lancet; 2023 Sep; 402(10405):859-870. PubMed ID: 37591292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Keluoxin capsule combined with losartan potassium on diabetic kidney disease: study protocol for a randomized double-blind placebo-controlled multicenter clinical trial.
    Wu R; Wei F; Qu L; Bai L; Li J; Li F; Yan W; Wang Q; Wei J
    Trials; 2020 Nov; 21(1):951. PubMed ID: 33228726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term renal survival and undetected risk factors of IgA nephropathy in Chinese children-a retrospective 1243 cases analysis from single centre experience.
    Wu H; Fang X; Xia Z; Gao C; Peng Y; Li X; Zhang P; Kuang Q; Wang R; Wang M
    J Nephrol; 2020 Dec; 33(6):1263-1273. PubMed ID: 32507961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of Shenyankangfu tablets for primary glomerulonephritis: study protocol for a randomized controlled trial.
    Kou J; Wu J; Yang HT; He YN; Fang JA; Deng YY; Xie YS; Nie LF; Lin HL; Cai GY; Chen XM
    Trials; 2014 Dec; 15():479. PubMed ID: 25480673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Leflunomide, Telmisartan, and Clopidogrel for Immunoglobulin A Nephropathy: A Randomized Controlled Trial.
    Wu J; Duan SW; Sun XF; Li WG; Wang YP; Liu WH; Zhang JR; Lun LD; Li XM; Zhou CH; Li JJ; Liu SW; Xie YS; Cai GY; Ma L; Huang W; Wu H; Jia Q; Chen XM
    Chin Med J (Engl); 2016 Aug; 129(16):1894-903. PubMed ID: 27503012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.